Literature DB >> 19047470

Dexamethasone induction of murine CYP2B genes requires the glucocorticoid receptor.

Etienne Audet-Walsh1, Alan Anderson.   

Abstract

Hepatic cytochrome P450 (P450) enzymes metabolize exogenous and endogenous compounds, and many are inducible by xenobiotics. Their synthesis is tightly regulated, particularly through nuclear receptors. Expression of murine CYP2B genes is strongly activated by treatment with phenobarbital or phenobarbital-like inducers, and a detectable response requires the presence of the constitutive androstane receptor (CAR). However, other compounds can also induce murine CYP2B proteins. For example, dexamethasone is known to induce rat CYP2B1 and CYP2B2 and mouse CYP2B10. Using human HepG2 and rat H4IIEC3 hepatoma cell lines, we found that dexamethasone induction of CYP2B2 and Cyp2b10 luciferase reporters required the glucocorticoid receptor. Given the well known observation that CYP2B genes are not phenobarbital-responsive in cultured cell lines, the dexamethasone responsiveness of CYP2B reporter constructs in cell lines demonstrates in itself that the mechanism of dexamethasone induction is distinct from that of phenobarbital. We also analyzed the relative importance of the phenobarbital response unit (PBRU) and of a known glucocorticoid response element in this response. Both sites contributed to the response, but other sites were required for maximal induction. CAR was also found to act as an accessory factor to stimulate the response to dexamethasone by the glucocorticoid receptor. Furthermore, in H4IIEC3 cells, CAR activated the PBRU in the natural sequence context of the CYP2B2 and Cyp2b10 5' flanks. In summary, there are at least two independent mechanisms of CYP2B induction: one involving phenobarbital and phenobarbital-like inducers and another involving glucocorticoids that induce via the glucocorticoid receptor with CAR acting as an accessory factor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047470     DOI: 10.1124/dmd.108.022772

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

1.  Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

Authors:  Xia Yang; Bin Zhang; Cliona Molony; Eugene Chudin; Ke Hao; Jun Zhu; Andrea Gaedigk; Christine Suver; Hua Zhong; J Steven Leeder; F Peter Guengerich; Stephen C Strom; Erin Schuetz; Thomas H Rushmore; Roger G Ulrich; J Greg Slatter; Eric E Schadt; Andrew Kasarskis; Pek Yee Lum
Journal:  Genome Res       Date:  2010-06-10       Impact factor: 9.043

2.  Cyp2b-Knockdown Mice Poorly Metabolize Corn Oil and Are Age-Dependent Obese.

Authors:  Basma Damiri; William S Baldwin
Journal:  Lipids       Date:  2018-11-12       Impact factor: 1.880

3.  Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells.

Authors:  Raymond Lo; Lyle Burgoon; Laura Macpherson; Shaimaa Ahmed; Jason Matthews
Journal:  Biochim Biophys Acta       Date:  2010-01-14

4.  AealRACK1 expression and localization in response to stress in C6/36 HT mosquito cells.

Authors:  Cecilia González-Calixto; Febe E Cázares-Raga; Leticia Cortés-Martínez; Rosa María Del Angel; Fernando Medina-Ramírez; Clemente Mosso; Ramón Ocádiz-Ruiz; Jesús G Valenzuela; Mario Henry Rodríguez; Fidel de la Cruz Hernández-Hernández
Journal:  J Proteomics       Date:  2014-12-30       Impact factor: 4.044

Review 5.  Insights into CYP2B6-mediated drug-drug interactions.

Authors:  William D Hedrich; Hazem E Hassan; Hongbing Wang
Journal:  Acta Pharm Sin B       Date:  2016-08-09       Impact factor: 11.413

6.  Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid-induced skin atrophy.

Authors:  Gleb Baida; Pankaj Bhalla; Alexander Yemelyanov; Lance A Stechschulte; Weinian Shou; Ben Readhead; Joel T Dudley; Edwin R Sánchez; Irina Budunova
Journal:  Oncotarget       Date:  2018-10-05

7.  Important role of kallikrein 6 for the development of keratinocyte proliferative resistance to topical glucocorticoids.

Authors:  Mari Kishibe; Gleb Baida; Pankaj Bhalla; Robert M Lavker; Bethanee Schlosser; Sin Iinuma; Shigetaka Yoshida; Joel T Dudley; Irina Budunova
Journal:  Oncotarget       Date:  2016-10-25

8.  The Influence of Long-Term Treatment with Asenapine on Liver Cytochrome P450 Expression and Activity in the Rat. The Involvement of Different Mechanisms.

Authors:  Przemysław J Danek; Ewa Bromek; Władysława A Daniel
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.